# Botulinum Toxin Injection in the UES for R-CPD

> **NCT06356025** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **AZ Delta** · enrollment: 50 (estimated)

## Conditions studied

- Retrograde Cricopharyngeus Dysfunction

## Interventions

- **DRUG:** botulinum toxin type A
- **DRUG:** Sodium Chloride 0.9% Inj

## Key facts

- **NCT ID:** NCT06356025
- **Lead sponsor:** AZ Delta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2025-12
- **Final completion:** 2027-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356025, "Botulinum Toxin Injection in the UES for R-CPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06356025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*